Bausch & Lomb Corp BLCO
Bausch + Lomb Corporation (and its subsidiaries) ("Bausch + Lomb," "we," "us," "our" or the "Company") is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Our mission is simple, yet powerful: helping you see better, to live better. Founded in 1853, Bausch + Lomb has a significant global research, development, manufacturing and commercial footprint of approximately 13,000 employees and a presence in approximately 100 countries. As a fully integrated eye health business, Bausch + Lomb has a comprehensive portfolio of approximately 400 products, which includes an established line of contact lenses, intraocular lenses ("IOLs") and other medical devices, surgical systems and devices, vitamin and mineral supplements, lens care products, prescription eye-medications and other consumer products that positions us to compete in all areas of the eye health market.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $5.10B | $4.79B | $4.15B | $3.77B | $3.77B | $3.41B | — |
| SG&A | $2.23B | $2.08B | $1.74B | $1.48B | $1.39B | $1.25B | — |
| Total operating expenses | $4.99B | $4.63B | $4.02B | $3.56B | $3.44B | $3.15B | — |
| Operating income | $113.0M | $162.0M | $130.0M | $207.0M | $329.0M | $260.0M | — |
| Pre-tax income | -$317.0M | -$234.0M | -$166.0M | $73.0M | $318.0M | $290.0M | — |
| Income tax | $35.0M | $71.0M | $82.0M | $58.0M | $125.0M | $307.0M | — |
| Net income | -$360.0M | -$317.0M | -$260.0M | $6.0M | $182.0M | -$18.0M | — |
| EPS, basic | -1.02 | -0.90 | -0.74 | 0.02 | 0.52 | -0.05 | — |
| EPS, diluted | -1.02 | -0.90 | -0.74 | 0.02 | 0.52 | -0.05 | — |
| Shares, diluted (wtd. avg.) | $353.8M | $351.8M | $350.5M | $350.2M | $350.0M | $350.0M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $383.0M | $305.0M | $334.0M | $380.0M | $177.0M | $238.0M | $192.0M |
| Receivables | $1.22B | $1.03B | $839.0M | $724.0M | $721.0M | — | — |
| Inventory | $976.0M | $1.04B | $1.03B | $628.0M | $572.0M | — | — |
| Total current assets | $2.98B | $2.79B | $2.74B | $2.14B | $1.64B | — | — |
| Property, plant and equipment | $1.76B | $1.49B | $1.39B | $1.30B | $1.23B | — | — |
| Goodwill | $4.76B | $4.52B | $4.58B | $4.51B | $4.59B | $4.68B | $4.55B |
| Other intangibles | $3.28B | $3.49B | $3.59B | $2.06B | $2.26B | — | — |
| Total assets | $14.02B | $13.47B | $13.44B | $11.14B | $10.82B | — | — |
| Accounts payable | $388.0M | $389.0M | $522.0M | $370.0M | $239.0M | — | — |
| Short-term debt | $28.0M | $40.0M | $30.0M | $25.0M | $0 | — | — |
| Total current liabilities | $1.92B | $1.74B | $1.58B | $1.30B | $1.10B | — | — |
| Long-term debt | $5.02B | $4.74B | $4.53B | $2.41B | $0 | — | — |
| Total liabilities | $7.50B | $6.92B | $6.52B | $4.04B | $1.42B | — | — |
| Retained earnings | -$931.0M | -$571.0M | -$254.0M | $6.0M | $0 | — | — |
| Total equity | $6.45B | $6.47B | $6.92B | $7.10B | $9.40B | $9.99B | $10.03B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $283.0M | $232.0M | -$17.0M | $345.0M | $873.0M | $522.0M | — |
| Depreciation and amortisation | $163.0M | $148.0M | $142.0M | $135.0M | $123.0M | $119.0M | — |
| Stock-based compensation | $149.0M | $92.0M | $74.0M | $62.0M | $62.0M | $50.0M | — |
| Capital expenditure | $349.0M | $291.0M | $181.0M | $175.0M | $193.0M | $253.0M | — |
| Investing cash flow | -$455.0M | -$412.0M | -$2.11B | -$215.0M | -$214.0M | -$256.0M | — |
| Financing cash flow | $225.0M | $178.0M | $2.08B | $81.0M | -$712.0M | -$232.0M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-014234.
Others in SIC 3851
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| COO | COOPER COMPANIES, INC. | $13.57B | 37.2x | 5.1% |
| WRBY | Warby Parker Inc. | $3.02B | 2,435.0x | 13.0% |
| EYE | National Vision Holdings, Inc. | $1.32B | 45.2x | 9.0% |
| STAA | STAAR SURGICAL CO | $1.18B | — | -23.7% |
| RXST | RxSight, Inc. | $265.2M | — | -3.9% |
| LUCYW | Innovative Eyewear Inc | $275.5K | — | 62.6% |
| ALC | ALCON INC | — | — | 4.9% |